SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Karlén Anders) "

Sökning: WFRF:(Karlén Anders)

  • Resultat 1-10 av 164
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Wan, Y., et al. (författare)
  • First reported nonpeptide AT1 receptor agonist (L-162,313) acts as an AT2 receptor agonist in vivo
  • 2004
  • Ingår i: J Med Chem. - : American Chemical Society (ACS). - 0022-2623 .- 1520-4804. ; 47:6, s. 1536-1546
  • Tidskriftsartikel (refereegranskat)abstract
    • In this investigation, it is demonstrated that the first nonpeptide AT(1) receptor agonist L-162,313 (1), disclosed in 1994, also acts as an agonist at the AT(2) receptor. In anesthetized rats, administration of compound 1 intravenously or locally in the duodenum increased duodenal mucosal alkaline secretion, effects that were sensitive to the selective AT(2) receptor antagonist PD-123,319. The data strongly suggest that 1 is an AT(2) receptor agonist in vivo. To the best of our knowledge, this substance is the first nonpeptidic low-molecular weight compound with an agonistic effect mediated through the AT(2) receptor.
  •  
2.
  • Andersson, Hanna, 1979-, et al. (författare)
  • Potent Macrocyclic Inhibitors of Insulin-Regulated Aminopeptidase (IRAP) by Olefin Ring-Closing Metathesis
  • 2011
  • Ingår i: Journal of Medicinal Chemistry. - : American Chemical Society (ACS). - 0022-2623 .- 1520-4804. ; 51, s. 3779-3792
  • Tidskriftsartikel (refereegranskat)abstract
    • Macrocyclic analogues of angiotensin IV (Ang IV, Val1-Tyr2-Ile3-His4-Pro5-Phe6) targeting the insulin-regulated aminopeptidase (IRAP) have been designed, synthesized, and evaluated biologically. Replacement of His4-Pro5-Phe6 by a 2-(aminomethyl)phenylacetic acid (AMPAA) moiety and of Val1 and Ile3 by amino acids bearing olefinic side chains followed by macrocyclization provided potent IRAP inhibitors. The impact of the ring size and the type (saturated versus unsaturated), configuration, and position of the carbon–carbon bridge was assessed. The ring size generally affects the potency more than the carbon–carbon bond characteristics. Replacing Tyr2 by β3hTyr or Phe is accepted, while N-methylation of Tyr2 is deleterious for activity. Removal of the carboxyl group in the C-terminal slightly reduced the potency. Inhibitors 7 (Ki = 4.1 nM) and 19 (Ki = 1.8 nM), both encompassing 14-membered ring systems connected to AMPAA, are 10-fold more potent than Ang IV and are also more selective over aminopeptidase N (AP-N). Both compounds displayed high stability against proteolysis by metallopeptidases.
  •  
3.
  •  
4.
  • Andersson, Hanna, 1979- (författare)
  • Design and Synthesis of Angiotensin IV Peptidomimetics Targeting the Insulin-Regulated Aminopeptidase (IRAP)
  • 2010
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
    • Peptidomimetics derived from the bioactive hexapeptide angiotensin IV (Ang IV, Val1-Tyr2-Ile3-His4-Pro5-Phe6) have been designed and synthesized. These peptidomimetics are aimed at inhibiting the insulin-regulated amino peptidase (IRAP), also known as the AT4 receptor. This membrane-bound zinc-metallopeptidase is currently under investigation regarding its potential as a target for cognitive enhancers. The work presented herein was based on stepwise replacement of the amino acid residues in Ang IV by natural and unnatural amino acids, non-peptidic building blocks, and also on the introduction of conformational constraints. Initially, we focused on the introduction of secondary structure mimetics and backbone mimetics. The C-terminal tripeptide His-Pro-Phe was successfully replaced by a γ-turn mimetic scaffold, 2-(aminomethyl)phenylacetic acid (AMPA), which was coupled via an amide bond to the carboxyl terminus of Val-Tyr-Ile. Substitution of Val-Tyr-Ile, Val-Tyr, Tyr-Ile and Tyr, respectively, by 4-hydroxydiphenylmethane scaffolds comprising a 1,3,5-substituted benzene ring as a central moiety unfortunately rendered peptidomimetics that were less potent than Ang IV. The subsequent approach involved the introduction of conformational constraints into Val-Tyr-Ile-AMPA by replacing Val and Ile by amino acid residues appropriate for disulfide cyclization or ring-closing metathesis. Chemically diverse structures encompassing an N-terminal 13- or 14-membered macrocyclic tripeptide and a C-terminal non-peptidic moiety were developed. Tyr2 and AMPA were modified to acquire further knowledge about the structure-activity relationships and, in addition, to improve the metabolic stability and reduce the polarity. Several of the compounds displayed a high capacity to inhibit IRAP and exhibited Ki values in the low nanomolar range. Hence, the new compounds were more than ten times more potent than the parent peptide Ang IV. Enhanced selectivity over the closely related aminopeptidase N (AP-N) was achieved, as well as improved stability against proteolysis by metallopeptidases present in the assays. However, additional investigations are required to elucidate the bioactive conformation(s) of the relatively flexible N-terminal macrocycles. The compounds presented in this thesis have provided important information on structure-activity relationships regarding the interaction of Ang IV-related pseudopeptides and peptidomimetics with IRAP. The best compounds in the series constitute important starting points for further discovery of Ang IV peptidomimetics suitable as tools in the investigation of IRAP and other potential targets for Ang IV. The literature presents strong support for the hypothesis that drug-like IRAP inhibitors would serve as a new type of future cognitive enhancers with potential use in the treatment of cognitive disorders, e.g. Alzheimer’s disease.
  •  
5.
  • Andersson, Hanna, 1979-, et al. (författare)
  • Disulfide cyclized tripeptide analogues of angiotensin IV as potent and selective inhibitors of insulin-regulated aminopeptidase (IRAP)
  • 2010
  • Ingår i: Journal of Medicinal Chemistry. - : American Chemical Society (ACS). - 0022-2623 .- 1520-4804. ; 53:22, s. 8059-8071
  • Tidskriftsartikel (refereegranskat)abstract
    • The insulin-regulated aminopeptidase (IRAP) localized in areas of the brain associated with memory and learning is emerging as a new promising therapeutic target for the treatment of memory dysfunctions. The angiotensin II metabolite angiotensin IV (Ang IV, Val1-Tyr2-Ile3-His4-Pro5-Phe6) binds with high affinity to IRAP and inhibits this aminopeptidase (Ki = 62.4 nM). Furthermore, Ang IV has been demonstrated to enhance cognition in animal models and seems to play an important role in cognitive processes. It is herein reported that displacement of the C-terminal tripeptide His4-Pro5-Phe6 with a phenylacetic acid functionality combined with a constrained macrocyclic system in the N-terminal affords potent IRAP inhibitors that are less peptidic in character than the hexapeptide Ang IV. The best inhibitors in the series, compound 8 and 12, incorporating a 13- and 14-membered disulfide ring system, respectively, and both with a β3-homotyrosine residue (β3hTyr) replacing Tyr2, exhibit Ki values of 3.3 nM and 5.2 nM, respectively.
  •  
6.
  • Ax, Anna, 1975- (författare)
  • Cyclic Sulfamide HIV-1 Protease Inhibitors : Design, Synthesis and Modelling
  • 2005
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
    • Ten years ago, the first protease inhibitor targeting the human immunodeficiency virus (HIV) was approved for clinical use. Highly active antiretroviral therapy (HAART), which combined protease and reverse transcriptase inhibitors, quickly became the standard therapy for treating patients infected with HIV and Acquired Immune Deficiency Syndrome (AIDS). Nevertheless, last year the AIDS pandemic reached its highest level ever. Many infected patients, mainly in the developing countries, are still without treatment. Among those patients who receive treatment, an increase in drug resistance and new-infection with drug-resistant strains are seen. To come to terms with these problems, new drugs that are efficient against resistant strains and can be produced at low cost are needed.In this study, we have focused our research efforts on cyclic sulfamides active as HIV-1 protease inhibitors. Distinctive to this compound class, as compared to the inhibitors so far approved for clinical use, was the incorporation of a water mimic that displaces the structural water (W301) observed in the X-ray crystal co-complexes. The first part of the study was aimed at understanding the rationale behind the nonsymmetric binding mode that the inhibitor adopted when bound to the enzyme. Symmetric and nonsymmetric inhibitors were synthesized and the structure-activity relationships and preferable binding modes were rationalized with the help of Comparative Molecular Field Analysis (CoMFA).In the second part of the study, an attempt was made to reduce the size of these inhibitors. As a result, the traditional P1/P1' substituents were removed, while the P2/P2' substituents were elongated in an attempt to reach between the binding sites. The design hypothesis was shown to be successful and inhibitors possessing nanomolar activity were identified.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  • Ax, Anna, et al. (författare)
  • Synthesis of a small library of non-symmetric cyclic sulfamide HIV-1 protease inhibitors
  • 2010
  • Ingår i: Tetrahedron. - : Elsevier BV. - 0040-4020 .- 1464-5416. ; 66:23, s. 4049-4056
  • Tidskriftsartikel (refereegranskat)abstract
    • A set of 11 non-symmetric cyclic sulfamide HIV-1 protease inhibitors were synthesized and evaluated. The use of a key microwave-assisted silver(I) oxide mediated selective mono N-benzylation reaction enabled fast and straightforward synthesis. The K-i values of the new inhibitors ranged between 0.28 mu M and >20 mu M.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 164
Typ av publikation
tidskriftsartikel (117)
doktorsavhandling (24)
annan publikation (12)
konferensbidrag (6)
forskningsöversikt (5)
Typ av innehåll
refereegranskat (122)
övrigt vetenskapligt/konstnärligt (41)
populärvet., debatt m.m. (1)
Författare/redaktör
Karlén, Anders (124)
Hallberg, Anders (40)
Lindeberg, Gunnar (28)
Larhed, Mats (23)
Samuelsson, Bertil (16)
Gogoll, Adolf (16)
visa fler...
Danielson, U. Helena (16)
Schaal, Wesley (14)
Sandström, Anja (14)
Unge, Torsten (13)
Sköld, Christian (13)
Nyberg, Fred (12)
Karlén, Anders, Prof ... (11)
Åkerblom, Eva (11)
Mowbray, Sherry L. (10)
Botros, Milad (10)
Alogheli, Hiba (9)
Classon, Björn (9)
Vrang, Lotta (8)
Brandt, Peter (8)
Hertervig, Erik (8)
Hallberg, Mathias (8)
Rosenström, Ulrika (6)
Zamora, Ismael (6)
Hultén, Johan (6)
Nillroth, Ulrika (6)
Gallo-Payet, Nicole (6)
Erdélyi, Máté (6)
Gising, Johan (6)
Mowbray, Sherry L, 1 ... (6)
Odell, Luke R (5)
Erdelyi, Mate, 1975 (5)
Hughes, Diarmaid, 19 ... (5)
Bengtsson, Jörgen, 1 ... (5)
Afzelius, Lovisa (5)
Andersson, Tommy B. (5)
Enoksson, Peter, 195 ... (5)
Fahlke, Claudia, 196 ... (5)
Granhag, Pär-Anders, ... (5)
Befrits, Ragnar (5)
Lindh, Martin, 1981- (5)
Srinivasa, Bachally ... (5)
Söderpalm Gordh, Ann ... (5)
Hallberg, Anders, Pr ... (5)
Demaegdt, Heidi (5)
Vauquelin, Georges (5)
Cao, Sha (5)
Hedsten, Karin, 1964 (5)
Ax, Anna (5)
Hildebrand Karlén, M ... (5)
visa färre...
Lärosäte
Uppsala universitet (142)
Göteborgs universitet (11)
Karolinska Institutet (11)
Örebro universitet (8)
Chalmers tekniska högskola (7)
Linköpings universitet (6)
visa fler...
Lunds universitet (6)
Umeå universitet (4)
Sveriges Lantbruksuniversitet (2)
Kungliga Tekniska Högskolan (1)
Stockholms universitet (1)
Mittuniversitetet (1)
Linnéuniversitetet (1)
Försvarshögskolan (1)
Sophiahemmet Högskola (1)
visa färre...
Språk
Engelska (150)
Odefinierat språk (12)
Svenska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (87)
Naturvetenskap (38)
Teknik (7)
Samhällsvetenskap (6)
Lantbruksvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy